Close Menu

NEW YORK – Myriad Genetics said Monday that it has submitted a supplementary application to the Japanese Ministry of Health Labor and Welfare for use of its BRACAnalysis Diagnostic System as a companion diagnostic to identify patients with metastatic pancreatic or metastatic castration-resistant prostate cancer who have germline BRCA1 and BRCA2 mutations and may be candidates for targeted therapy with the PARP inhibitor olaparib (AstraZeneca's Lynparza), subject to regulatory approval.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Forbes reports that a structural biology lab at Oxford University studying the coronavirus was hacked.

Politico reports that the NYPD DNA database has grown since it announced it would be removing profiles from it.

Science reports that a Dutch research funding agency is combating a ransomware attack.

In Science this week: set of 64 haplotype assemblies from 32 individuals, and more.